COVID antibodies may reduce reinfection, but vaccines can provide additional protection | Michigan Medicine
COVID-19 antibodies persist, reduce reinfection risk for up to six months, study finds
Health Lab · Michigan Medicine Department of Communication
Audio is streamed directly from the publisher (sphinx.acast.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
A Michigan Medicine study found that most patients with mild COVID-19 infections produce antibodies that persist and protect them from reinfection for up to six months. Lead author Charles Schuler, M.D. recommends those eligible for vaccination should still get the COVID vaccine, stating, "Achieving natural immunity by deferring vaccination in favor of infection is not worth going through the discomfort, risk to yourself and risk to others."
For the full text, visit: "COVID-19 antibodies persist, reduce reinfection risk for up to six months, study finds."
Don't forget to subscribe to the Michigan Medicine News Break on Apple, Spotify or wherever you listen to podcasts, and check out all of the shows on the Michigan Medicine Podcast Network.
Hosted on Acast. See acast.com/privacy for more information.